Geyer CE, Forster JF, Lindquist DL, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006 ; 355 : 2733.
Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer : final survival analysis of a phase III randomized trial. Oncologist 2010 ; 15 : 924.
Pivot X, Semiglazov X, Żurawski B, et al. CEREBEL (EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab plus capecitabine (TC) [abstract LBA11]. Ann Oncol 2012 ; 23 Supple 9 : ixe5.